Last reviewed · How we verify
Detantol (BUNAZOSIN)
Detantol (generic name: BUNAZOSIN) is a bunazosin drug. It is currently in Phase 3 development for Essential hypertension.
Detanidol works by blocking the alpha-1A adrenergic receptor, which helps to relax blood vessels and lower blood pressure.
Detanidol (Bunazosin) is a small molecule drug that targets the alpha-1A adrenergic receptor. It is classified as a bunazosin and is used to treat essential hypertension. The commercial status of Detanidol is unknown, and it is not FDA-approved. Key safety considerations include its short half-life of 2.0 hours and moderate bioavailability of 44%. Further research is needed to determine its off-patent status and generic manufacturers.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | BUNAZOSIN |
|---|---|
| Drug class | bunazosin |
| Target | Alpha-1A adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Think of it like a traffic light: when the alpha-1A receptor is active, it's like a red light that makes blood vessels constrict. By blocking this receptor, Detanidol is like flipping the light to green, allowing blood vessels to relax and blood pressure to decrease.
Approved indications
- Essential hypertension
Common side effects
Key clinical trials
- The Effect of Continuous Positive Airway Therapy on the Blood Pressure in Sleepy vs Non-sleepy Patients With Obstructive Sleep Apnea
- The Effect of Different Types of Music on Pain and Anxiety During Wound Care Procedures in Patients With Venous Ulcers (NA)
- Potential Benefits of Sonic Augmentation Technology in Music (NA)
- Management of Non-Organic Dysphonia in Adults. (NA)
- B0151005 Open-Label Extension Study (PHASE2)
- A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy (PHASE2)
- Effects of Combination Therapy With Alpha-1 Blocker (Bunazosin or Doxazosin) in the Treatment of Patients With Mild to Moderate Essential Hypertension (PHASE4)
- Clinical Use of Andante SmartStep System in Gait Rehabilitation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Detantol CI brief — competitive landscape report
- Detantol updates RSS · CI watch RSS
Frequently asked questions about Detantol
What is Detantol?
How does Detantol work?
What is Detantol used for?
What is the generic name of Detantol?
What drug class is Detantol in?
What development phase is Detantol in?
What does Detantol target?
Related
- Drug class: All bunazosin drugs
- Target: All drugs targeting Alpha-1A adrenergic receptor
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Essential hypertension
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing